Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms, animal studies, and sparse clinical literature without systematic methods
What was done
This narrative review evaluated epidemiologic, clinical, animal, and in vitro evidence concerning the role of estradiol and selective estrogen receptor modulators (SERMs) in schizophrenia and Parkinson's disease. The authors reviewed estrogenic modulation of neurotransmitter systems (dopamine, serotonin, glutamate) and neuroprotective effects, alongside novel data on SERM effects on 5-HT2A receptors in rat cortex and nucleus accumbens.
What was found
No quantitative findings or effect sizes are reported in the abstract. The authors note that while animal and in vitro models consistently demonstrate neuromodulatory and neuroprotective actions of estrogens, clinical and epidemiologic evidence in humans is sparse and often contradictory.
Why it matters
Understanding the tissue-specific neuromodulatory actions of brain-active SERMs could help identify targets for adjunctive therapies in schizophrenia and Parkinson's disease.
Limits
The paper is an unsystematic narrative review combining animal, in vitro, and descriptive human data. Human clinical findings are sparse and contradictory, and no systematic search criteria or sample sizes are provided in the abstract.
Cited by
- context Loss of estrogen in the brain causes a drop in dopamine levels.